Home Non-Invasive Ventilation (NIV) in Chronic Lung Disease

← Back to Index (πŸ”¬Recent Advances)

Clinical Rationale And Core Objectives

Primary Clinical Indications

Disease Category Specific Pathology Recommended Modality And Rationale
Neuromuscular Disorders Duchenne Muscular Dystrophy (DMD), Spinal Muscular Atrophy (SMA) Early initiation of nocturnal BiPAP (Bilevel Positive Airway Pressure) to manage sleep-disordered breathing, avert chronic hypoxia, and prevent secondary cor pulmonale.
Neonatal Chronic Lung Disease Evolving Or Established Bronchopulmonary Dysplasia (BPD) Facilitates extended periods of non-invasive support, reduces the necessity for systemic corticosteroids, and stabilizes fluctuating oxygen saturations.

Monitoring Protocols For Home NIV

Non-Invasive Carbon Dioxide Tracking

Monitoring Technique Clinical Application Guideline Endorsements
Transcutaneous CO2 (TcCO2) Tracks steady-state ventilation during NIV usage at home; supports ambulatory monitoring in neuromuscular disease. American Association for Respiratory Care (AARC) recommends TcCO2 for NIV assessment. Values must remain within 7.5 mmHg of actual PaCO2.
End-Tidal CO2 (EtCO2) Provides real-time assessment of ventilation-perfusion matching during sleep studies. ESPGHAN/NASPGHAN (2025) strongly endorses EtCO2 for NIV and pediatric sleep study evaluation.

Diagnostic Thresholds For Hypoventilation

Advanced Physiological Support Strategies

Neurally Adjusted Ventilatory Assist (NIV-NAVA)

Tele-Pediatric Integration

Implementation Challenges In The Indian Context